European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2026
TricValve system implantation in patients with cardiac implantable electronic devices: A multicentre observational study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osipenko Kira, Coti Iuliana, Werner Paul, Kahrovic Amila, Franco Luis Nombela, Amat Santos Ignacio J, Mahabadi Amir A, Frerker Christian, De Marco Federico, Althoff Jan, Mangieri Antonio, Moreiras Javier Martín, Pavlović Nikola, Schofer Joachim, Schäfer Ulrich, Tigges Eike, Wilde Christoph, Hausleiter Jörg, Altisent Omar Abdul-Jawad, Taramasso Maurizio, Valbuena Luis Fernando Pajín, Bulum Joško, Ordoñez Santiago, Swaans Martin, Marques João Silva, Dickmann Boris, Zirngast Birgit, Zimpfer Daniel, Andreas Martin
Аннотация
OBJECTIVES: Tricuspid regurgitation (TR) is associated with high morbidity and mortality. The TricValve bicaval valve system has emerged as a transcatheter option for patients with severe symptomatic TR who are not candidates for surgery or orthotopic interventions. However, its safety in patients with pre-existing cardiac implantable electronic devices (CIED) remains uncertain due to potential lead-related complications. This study aims to evaluate the feasibility and safety of TricValve implantation in patients with pre-existing CIED, with particular focus on lead-related complications and the need for lead extraction or repositioning.
METHODS: We conducted a multicentre retrospective study including 65 patients with pre-implanted CIED who underwent TricValve implantation between May 2023 and November 2024 at 23 international centres. Pre-procedural computed tomography and echocardiography were analyzed to assess device interaction, lead positioning, and complications. The primary endpoint was procedural safety, including lead-related events and the need for lead extraction or repositioning during intervention. Secondary endpoints included echocardiographic outcomes, CIED/non-CIED-related complications and survival during follow-up of 159 days (IQR 60-358 days).
RESULTS: TricValve implantation was technically successful in all patients (100%). Periprocedural no lead extraction or repositioning was required. Lead-related complications occurred in 4 patients (6.2%). No procedural deaths or TricValve malfunctions were observed. Post-implantation imaging confirmed stable lead positioning in all remaining cases.
CONCLUSIONS: TricValve implantation in patients with pre-existing CIED appears feasible. Lead-related complications during early follow-up were rare, manageable, and did not compromise device function or procedural success. Our data do not support routine prophylactic lead extraction before TricValve implantation.
METHODS: We conducted a multicentre retrospective study including 65 patients with pre-implanted CIED who underwent TricValve implantation between May 2023 and November 2024 at 23 international centres. Pre-procedural computed tomography and echocardiography were analyzed to assess device interaction, lead positioning, and complications. The primary endpoint was procedural safety, including lead-related events and the need for lead extraction or repositioning during intervention. Secondary endpoints included echocardiographic outcomes, CIED/non-CIED-related complications and survival during follow-up of 159 days (IQR 60-358 days).
RESULTS: TricValve implantation was technically successful in all patients (100%). Periprocedural no lead extraction or repositioning was required. Lead-related complications occurred in 4 patients (6.2%). No procedural deaths or TricValve malfunctions were observed. Post-implantation imaging confirmed stable lead positioning in all remaining cases.
CONCLUSIONS: TricValve implantation in patients with pre-existing CIED appears feasible. Lead-related complications during early follow-up were rare, manageable, and did not compromise device function or procedural success. Our data do not support routine prophylactic lead extraction before TricValve implantation.